Erratum: (Arteriosclerosis, Thrombosis, and Vascular Biology (2013) 33 (1036-1045) DOI: 10.1161/ATVBAHA.112.300580);Inactivation of nuclear factor-Y inhibits vascular smooth muscle cell proliferation and neointima formation

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 33, Issue 5, 2013, Pages 1036-1045

  Silvestre Roig, Carlos ^a   Fernández, Patricia ^a   Esteban, Vanesa ^a   Pello, Óscar M ^a   Indolfi, Ciro ^b   Rodríguez, Cristina ^c   Rodríguez Calvo, Ricardo ^c   López Maderuelo, María Dolores ^a   Bauriedel, Gerhard ^d   Hutter, Randolph ^e   Fuster, Valentín ^a   Ibáñez, Borja ^a,f   Redondo, Juan M ^a   Martínez González, José ^c   Andrés, Vicente ^a,e  

^a CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^c Institut Català de Ciències Cardiovasculars   (Spain)

^d UNIVERSITY OF BONN   (Germany)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

atherosclerosis; cyclin B1; nuclear factor Y; restenosis; vascular smooth muscle cell proliferation

Indexed keywords

CYCLIN B1; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MUTANT PROTEIN; NUCLEAR FACTOR Y; PLATELET DERIVED GROWTH FACTOR BB; PROTEIN KINASE B;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INJURY; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CELL PROLIFERATION; CONTROLLED STUDY; DNA BINDING; ENDOTHELIUM CELL; ENZYME ACTIVATION; FEMORAL ARTERY; HUMAN; HUMAN CELL; HUMAN TISSUE; MACROPHAGE; MOUSE; NEOINTIMA; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; RESTENOSIS; SMOOTH MUSCLE FIBER; UPREGULATION; VASCULAR SMOOTH MUSCLE;

EID: 84876282332     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATV.0b013e318297ca8d     Document Type: Erratum

References (28)

1. Andrés V, Castro C. Antiproliferative strategies for the treatment of vascular proliferative disease. Curr Vasc Pharmacol. 2003;1:85-98.
2. Wessely R. New drug-eluting stent concepts. Nat Rev Cardiol. 2010;7:194-203.
3. Andrés V. Control of vascular cell proliferation and migration by cyclin-dependent kinase signalling: new perspectives and therapeutic potential. Cardiovasc Res. 2004;63:11-21.
4. Ekholm SV, Reed SI. Regulation of G(1) cyclin-dependent kinases in the mammalian cell cycle. Curr Opin Cell Biol. 2000;12:676-684.
5. Santamaría D, Ortega S. Cyclins and CDKS in development and cancer: lessons from genetically modifed mice. Front Biosci. 2006;11:1164-1188.
6. Braun-Dullaeus RC, Mann MJ, Seay U, Zhang L, von Der Leyen HE, Morris RE, Dzau VJ. Cell cycle protein expression in vascular smooth muscle cells in vitro and in vivo is regulated through phosphatidylinosi-tol 3-kinase and mammalian target of rapamycin. Arterioscler Thromb Vasc Biol. 2001;21:1152-1158.
7. Morishita R, Gibbons GH, Kaneda Y, Ogihara T, Dzau VJ. Pharmacokinetics of antisense oligodeoxyribonucleotides (cyclin B1 and CDC 2 kinase) in the vessel wall in vivo: enhanced therapeutic utility for restenosis by HVJ-liposome delivery. Gene. 1994;149:13-19.
8. Farina A, Manni I, Fontemaggi G, Tiainen M, Cenciarelli C, Bellorini M, Mantovani R, Sacchi A, Piaggio G. Down-regulation of cyclin B1 gene transcription in terminally differentiated skeletal muscle cells is associated with loss of functional CCAAT-binding NF-Y complex. Oncogene. 1999;18:2818-2827.
9. Porter LA, Donoghue DJ. Cyclin B1 and CDK1: nuclear localization and upstream regulators. Prog Cell Cycle Res. 2003;5:335-347.
10. Mantovani R. The molecular biology of the CCAAT-binding factor NF-Y. Gene. 1999;239:15-27.
11. Hu Q, Lu JF, Luo R, Sen S, Maity SN. Inhibition of CBF/NF-Y mediated transcription activation arrests cells at G2/M phase and suppresses expression of genes activated at G2/M phase of the cell cycle. Nucleic Acids Res. 2006;34:6272-6285.
12. Hu Q, Maity SN. Stable expression of a dominant negative mutant of CCAAT binding factor/NF-Y in mouse fbroblast cells resulting in retardation of cell growth and inhibition of transcription of various cellular genes. J Biol Chem. 2000;275:4435-4444.
13. Kotecha M, Kluza J, Wells G, O'Hare CC, Forni C, Mantovani R, Howard PW, Morris P, Thurston DE, Hartley JA, Hochhauser D. Inhibition of DNA binding of the NF-Y transcription factor by the pyr-rolobenzodiazepine-polyamide conjugate GWL-78. Mol Cancer Ther. 2008;7:1319-1328.
14. Morishita R, Gibbons GH, Ellison KE, Nakajima M, Zhang L, Kaneda Y, Ogihara T, Dzau VJ. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci USA. 1993;90:8474-8478.
15. Wei GL, Krasinski K, Kearney M, Isner JM, Walsh K, Andrés V. Temporally and spatially coordinated expression of cell cycle regulatory factors after angioplasty. Circ Res. 1997;80:418-426.
16. Raines EW. PDGF and cardiovascular disease. Cytokine Growth Factor Rev. 2004;15:237-254.
17. Mantovani R, Li X Y, Pessara U, Hooft van Huisjduijnen R, Benoist C, Mathis D. Dominant negative analogs of NF-YA. J Biol Chem. 1994;269:20340-20346.
18. Egloff AM, Vella LA, Finn OJ. Cyclin B1 and other cyclins as tumor antigens in immunosurveillance and immunotherapy of cancer. Cancer Res. 2006;66:6-9.
19. Sjin RM, Krishnaraju K, Hoffman B, Liebermann DA. Transcriptional regulation of myeloid differentiation primary response (MyD) genes during myeloid differentiation is mediated by nuclear factor Y. Blood. 2002;100:80-88.
20. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med. 2011;17:1410-1422.
21. Gurtner A, Manni I, Fuschi P, Mantovani R, Guadagni F, Sacchi A, Piaggio G. Requirement for down-regulation of the CCAAT-binding activity of the NF-Y transcription factor during skeletal muscle differentiation. Mol Biol Cell. 2003;14:2706-2715.
22. Choudhury GG, Karamitsos C, Hernandez J, Gentilini A, Bardgette J, Abboud HE. PI-3-kinase and MAPK regulate mesangial cell proliferation and migration in response to PDGF. Am J Physiol. 1997;273: F931-F938.
23. Choudhury GG, Mahimainathan L, Das F, Venkatesan B, Ghosh-Choudhury N. c-Src couples PI 3 kinase/Akt and MAPK signaling to PDGF-induced DNA synthesis in mesangial cells. Cell Signal. 2006;18:1854-1864.
24. Deuse T, Koyanagi T, Erben RG, Hua X, Velden J, Ikeno F, Reichenspurner H, Robbins RC, Mochly-Rosen D, Schrepfer S. Sustained inhibition of epsilon protein kinase C inhibits vascular restenosis after balloon injury and stenting. Circulation. 2010;122:S170-S178.
25. Mitra AK, Agrawal DK. In stent restenosis: bane of the stent era. J Clin Pathol. 2006;59:232-239.
26. Muslin AJ. MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets. Clin Sci. 2008;115:203-218.
27. Mattmann ME, Stoops SL, Lindsley CW. Inhibition of Akt with small molecules and biologics: historical perspective and current status of the patent landscape. Expert Opin Ther Pat. 2011;21:1309-1338.
28. Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci. 2011;36:320-328.